Global Cell Line Development for Biologics Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Cell Line Development for Biologics Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Cell line development is a critical step in the production of biologics. Biologics are complex molecules that are produced by living cells, such as proteins, antibodies, and vaccines. To produce biologics in large quantities, scientists need to develop cell lines that can produce these molecules consistently and at high levels.
Cell Line Development for Biologics report published by MRAResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Cell Line Development for Biologics market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Demand from Monoclonal Antibodies and Recombinant Proteins are the major drivers for the industry.
The global market for cell line development (CLD) in biologics has experienced substantial growth in recent years due to the increasing demand for biopharmaceutical products, including monoclonal antibodies, vaccines, and other therapeutic proteins. Cell line development is a critical step in the biomanufacturing process, involving the selection, optimization, and production of mammalian cell lines that can efficiently produce biologic drugs. The United States and Canada have a robust biopharmaceutical industry, making North America a major market for cell line development services. European countries have a significant presence in biologics development, with established pharmaceutical companies and research institutions driving demand for cell line development. The Asia-Pacific region is emerging as a key market due to its growing biopharmaceutical sector, increased investment in research and development, and access to skilled scientific talent. The cell line development for biologics market is projected to continue growing as biopharmaceutical companies strive to develop innovative and effective therapies. Technological advancements in automation, genomics, and synthetic biology are expected to further streamline and optimize the cell line development process.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Cell Line Development for Biologics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Lonza
Corning
Sartorius
Thermo Fisher Scientific
Selexis
Beckman Coulter (Danaher )
CYTENA
Molecular Devices
Samsung Biologics
Hera BioLabs
GTP Bioways
Abzena
FyoniBio
Catalent
WuXi Biologics
Segment by Type
CHO Cell Lines
HEK293 Cell Lines
Insect Cell Lines
Monoclonal Antibodies
Recombinant Proteins
Vaccines
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Cell Line Development for Biologics market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Cell Line Development for Biologics introduction, etc. Cell Line Development for Biologics Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Cell Line Development for Biologics market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.
Cell Line Development for Biologics report published by MRAResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Cell Line Development for Biologics market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Demand from Monoclonal Antibodies and Recombinant Proteins are the major drivers for the industry.
The global market for cell line development (CLD) in biologics has experienced substantial growth in recent years due to the increasing demand for biopharmaceutical products, including monoclonal antibodies, vaccines, and other therapeutic proteins. Cell line development is a critical step in the biomanufacturing process, involving the selection, optimization, and production of mammalian cell lines that can efficiently produce biologic drugs. The United States and Canada have a robust biopharmaceutical industry, making North America a major market for cell line development services. European countries have a significant presence in biologics development, with established pharmaceutical companies and research institutions driving demand for cell line development. The Asia-Pacific region is emerging as a key market due to its growing biopharmaceutical sector, increased investment in research and development, and access to skilled scientific talent. The cell line development for biologics market is projected to continue growing as biopharmaceutical companies strive to develop innovative and effective therapies. Technological advancements in automation, genomics, and synthetic biology are expected to further streamline and optimize the cell line development process.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Cell Line Development for Biologics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Lonza
Corning
Sartorius
Thermo Fisher Scientific
Selexis
Beckman Coulter (Danaher )
CYTENA
Molecular Devices
Samsung Biologics
Hera BioLabs
GTP Bioways
Abzena
FyoniBio
Catalent
WuXi Biologics
Segment by Type
CHO Cell Lines
HEK293 Cell Lines
Insect Cell Lines
Segment by Application
Monoclonal Antibodies
Recombinant Proteins
Vaccines
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Cell Line Development for Biologics market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Cell Line Development for Biologics introduction, etc. Cell Line Development for Biologics Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of Cell Line Development for Biologics market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices